{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T07:43:43Z","timestamp":1788248623081,"version":"build-2803163510"},"reference-count":74,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"48","license":[{"start":{"date-parts":[[2024,11,29]],"date-time":"2024-11-29T00:00:00Z","timestamp":1732838400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,11,29]]},"abstract":"<jats:p>Ankylosing spondylitis (AS) is a chronic inflammatory disease characterized by axial osteoarticular inflammation and tendon enthesitis with unclear pathogenesis. Nonsteroidal anti-inflammatory drugs and antirheumatic drugs used in the traditional treatment of AS have some problems such as drug intolerance and inadequate treatment response. Since the introduction of biological agents in the treatment of AS, they have completely changed the treatment concept of AS, and because of their safety and good tolerance, they have become the main choice for clinical AS patients. This article systematically summarizes the current status of targeted therapy for AS worldwide, analyzes the advantages and disadvantages of different types of biological agents in the treatment of AS, and provides an objective evaluation of clinical targeted therapy for AS, in order to provide a new perspective for clinical standardized treatment.<\/jats:p>","DOI":"10.1097\/md.0000000000040742","type":"journal-article","created":{"date-parts":[[2024,11,29]],"date-time":"2024-11-29T21:02:07Z","timestamp":1732914127000},"page":"e40742","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":3,"title":["Progress in targeted therapy for ankylosing spondylitis: A review"],"prefix":"10.1097","volume":"103","author":[{"given":"Jiapeng","family":"Wang","sequence":"first","affiliation":[{"name":"Department of Orthopedics, Jilin Province FAW General Hospital, Changchun City, Jilin Province, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wang","family":"Lou","sequence":"additional","affiliation":[{"name":"Department of Anesthesiology, Jilin Province FAW General Hospital, Changchun City, Jilin Province, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yingnan","family":"Li","sequence":"additional","affiliation":[{"name":"Burn the Brotherhood of Plastic Surgery, Jilin Province FAW General Hospital, Changchun City, Jilin Province, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang","family":"Jiang","sequence":"additional","affiliation":[{"name":"Department of Medical Laboratory, Jilin Province FAW General Hospital, Changchun City, Jilin Province, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xue","family":"Jiang","sequence":"additional","affiliation":[{"name":"Department of Rehabilitation, Jilin Province FAW General Hospital, Changchun City, Jilin Province, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-5612-3239","authenticated-orcid":false,"given":"Lin","family":"Yang","sequence":"additional","affiliation":[{"name":"Department of Anesthesiology, Jilin Province FAW General Hospital, Changchun City, Jilin Province, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20250503","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/S0140-6736(16)31591-4","article-title":"Axial spondyloarthritis.","volume":"390","author":"Sieper","year":"2017","journal-title":"Lancet"},{"key":"R2-20250503","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1016\/S0140-6736(07)60635-7","article-title":"Ankylosing spondylitis.","volume":"369","author":"Braun","year":"2007","journal-title":"Lancet"},{"key":"R3-20250503","doi-asserted-by":"crossref","first-page":"2563","DOI":"10.1056\/NEJMra1406182","article-title":"Ankylosing spondylitis and axial spondyloarthritis.","volume":"374","author":"Taurog","year":"2016","journal-title":"N Engl J Med"},{"key":"R4-20250503","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1007\/s11926-023-01097-7","article-title":"Have therapeutics enhanced our knowledge of axial spondyloarthritis? [published correction appears in Curr Rheumatol Rep. 2023 Apr 3;:].","volume":"25","author":"Harrison","year":"2023","journal-title":"Curr Rheumatol Rep"},{"key":"R5-20250503","doi-asserted-by":"crossref","first-page":"57","DOI":"10.2147\/OARRR.S295033","article-title":"Therapeutic targets for ankylosing spondylitis: recent insights and future prospects.","volume":"14","author":"Perrotta","year":"2022","journal-title":"Open Access Rheumatol"},{"key":"R6-20250503","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1016\/j.stem.2013.09.006","article-title":"Mesenchymal stromal cells: sensors and switchers of inflammation.","volume":"13","author":"Bernardo","year":"2013","journal-title":"Cell Stem Cell"},{"key":"R7-20250503","doi-asserted-by":"crossref","first-page":"5373","DOI":"10.1038\/s41467-021-25710-4","article-title":"TNF-\u03b1-mediated m6A modification of ELMO1 triggers directional migration of mesenchymal stem cell in ankylosing spondylitis.","volume":"12","author":"Xie","year":"2021","journal-title":"Nat Commun"},{"key":"R8-20250503","first-page":"CD005468","article-title":"TNF-alpha inhibitors for ankylosing spondylitis.","volume":"2015","author":"Maxwell","year":"2015","journal-title":"Cochrane Database Syst Rev"},{"key":"R9-20250503","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1007\/s00586-019-05912-7","article-title":"Radiologic parameters of ankylosing spondylitis patients treated with anti-TNF-\u03b1 versus nonsteroidal anti-inflammatory drugs and sulfasalazine.","volume":"28","author":"Son","year":"2019","journal-title":"Eur Spine J"},{"key":"R10-20250503","doi-asserted-by":"crossref","first-page":"159","DOI":"10.3904\/kjim.2013.28.2.159","article-title":"Patients treated with a tumor necrosis factor-\u03b1 inhibitor are more likely to develop extrapulmonary tuberculosis.","volume":"28","author":"Lee","year":"2013","journal-title":"Korean J Intern Med"},{"issue":"Suppl 1","key":"R11-20250503","doi-asserted-by":"crossref","first-page":"i46","DOI":"10.1136\/ard.59.suppl_1.i46","article-title":"Etanercept (Enbrel): update on therapeutic use.","volume":"59","author":"Spencer-Green","year":"2000","journal-title":"Ann Rheum Dis"},{"key":"R12-20250503","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1056\/NEJMoa012664","article-title":"Treatment of ankylosing spondylitis by inhibition of tumor necrosis factor alpha.","volume":"346","author":"Gorman","year":"2002","journal-title":"N Engl J Med"},{"key":"R13-20250503","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1186\/s13075-021-02428-8","article-title":"Structural changes in the sacroiliac joint on MRI and relationship to ASDAS inactive disease in axial spondyloarthritis: a 2-year study comparing treatment with etanercept in EMBARK to a contemporary control cohort in DESIR.","volume":"23","author":"Maksymowych","year":"2021","journal-title":"Arthritis Res Ther"},{"key":"R14-20250503","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1586\/1744666X.2016.1144472","article-title":"Etanercept for the treatment of non-radiographic axial spondyloarthritis.","volume":"12","author":"Rios Rodriguez","year":"2016","journal-title":"Expert Rev Clin Immunol"},{"key":"R15-20250503","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1007\/s40259-016-0188-z","article-title":"Etanercept (SB4): a review in autoimmune inflammatory diseases [published correction appears in BioDrugs. 2016 Oct;30(5):481].","volume":"30","author":"Burness","year":"2016","journal-title":"BioDrugs"},{"key":"R16-20250503","doi-asserted-by":"crossref","first-page":"6752","DOI":"10.2174\/1381612824666171129192040","article-title":"The experience with biosimilars of infliximab in rheumatic diseases.","volume":"23","author":"Azevedo","year":"2017","journal-title":"Curr Pharm Des"},{"key":"R17-20250503","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1002\/art.20852","article-title":"Efficacy and safety of infliximab in patients with ankylosing spondylitis: results of a randomized, placebo-controlled trial (ASSERT).","volume":"52","author":"van der Heijde","year":"2005","journal-title":"Arthritis Rheum"},{"key":"R18-20250503","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1093\/rheumatology\/keh584","article-title":"Persistent clinical response to the anti-TNF-alpha antibody infliximab in patients with ankylosing spondylitis over 3 years.","volume":"44","author":"Braun","year":"2005","journal-title":"Rheumatology (Oxford)"},{"key":"R19-20250503","doi-asserted-by":"crossref","first-page":"1690","DOI":"10.1093\/rheumatology\/ker194","article-title":"Persistent clinical efficacy and safety of infliximab in ankylosing spondylitis after 8 years: early clinical response predicts long-term outcome.","volume":"50","author":"Baraliakos","year":"2011","journal-title":"Rheumatology (Oxford)"},{"key":"R20-20250503","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1136\/ard.2006.058776","article-title":"Etanercept maintains the clinical benefit achieved by infliximab in patients with rheumatoid arthritis who discontinued infliximab because of side effects [published correction appears in Ann Rheum Dis. 2007 Jun;66(6):847. Monteccuco, Carlomaurizio [corrected to Montecucco, Carlomaurizio]].","volume":"66","author":"Iannone","year":"2007","journal-title":"Ann Rheum Dis"},{"key":"R22-20250503","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1080\/14397595.2018.1525024","article-title":"Real-world effectiveness and safety of adalimumab for treatment of ankylosing spondylitis in Japan.","volume":"29","author":"Kobayashi","year":"2019","journal-title":"Mod Rheumatol"},{"key":"R23-20250503","doi-asserted-by":"crossref","first-page":"2136","DOI":"10.1002\/art.21913","article-title":"Efficacy and safety of adalimumab in patients with ankylosing spondylitis: results of a multicenter, randomized, double-blind, placebo-controlled trial.","volume":"54","author":"van der Heijde","year":"2006","journal-title":"Arthritis Rheum"},{"key":"R24-20250503","doi-asserted-by":"crossref","first-page":"700570","DOI":"10.3389\/fimmu.2021.700570","article-title":"Adalimumab therapy restores the gut microbiota in patients with ankylosing spondylitis.","volume":"12","author":"Chen","year":"2021","journal-title":"Front Immunol"},{"key":"R25-20250503","doi-asserted-by":"crossref","first-page":"566160","DOI":"10.3389\/fmed.2020.566160","article-title":"Head-to-head comparison of etanercept vs. adalimumab in the treatment of ankylosing spondylitis: an open-label randomized controlled crossover clinical trial.","volume":"7","author":"Wei","year":"2020","journal-title":"Front Med (Lausanne)"},{"key":"R26-20250503","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1080\/03009742.2017.1330419","article-title":"Comparison of drug survival and clinical outcome in patients with ankylosing spondylitis treated with etanercept or adalimumab.","volume":"47","author":"Ruwaard","year":"2018","journal-title":"Scand J Rheumatol"},{"key":"R27-20250503","first-page":"83","article-title":"Efficacy and safety of adalimumab in ankylosing spondylitis.","volume":"6","author":"Mounach","year":"2014","journal-title":"Open Access Rheumatol"},{"key":"R28-20250503","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1007\/s40259-018-0318-x","article-title":"GP2017: an adalimumab biosimilar.","volume":"32","author":"Heo","year":"2018","journal-title":"BioDrugs"},{"key":"R29-20250503","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1007\/s40259-019-00335-8","article-title":"FKB327: an adalimumab biosimilar.","volume":"33","author":"Al-Salama","year":"2019","journal-title":"BioDrugs"},{"key":"R30-20250503","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1586\/eci.10.49","article-title":"Golimumab: a new anti-TNF-alpha agent for rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis.","volume":"6","author":"Voulgari","year":"2010","journal-title":"Expert Rev Clin Immunol"},{"key":"R31-20250503","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1080\/14712598.2017.1256387","article-title":"Golimumab for the treatment of axial spondyloarthritis.","volume":"17","author":"Palazzi","year":"2017","journal-title":"Expert Opin Biol Ther"},{"key":"R32-20250503","doi-asserted-by":"crossref","first-page":"2702","DOI":"10.1002\/art.39257","article-title":"A randomized, double-blind, placebo-controlled, sixteen-week study of subcutaneous golimumab in patients with active nonradiographic axial spondyloarthritis.","volume":"67","author":"Sieper","year":"2015","journal-title":"Arthritis Rheumatol"},{"key":"R33-20250503","doi-asserted-by":"crossref","first-page":"137","DOI":"10.4161\/mabs.2.2.11271","article-title":"Certolizumab pegol.","volume":"2","author":"Goel","year":"2010","journal-title":"MAbs"},{"key":"R34-20250503","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1358\/dot.2008.44.11.1278425","article-title":"Certolizumab pegol in Crohn\u2019s disease.","volume":"44","author":"Patel","year":"2008","journal-title":"Drugs Today (Barc)"},{"key":"R35-20250503","doi-asserted-by":"crossref","first-page":"e262","DOI":"10.1111\/1346-8138.15355","article-title":"Generalized pustular psoriasis in pregnancy, successfully treated with certolizumab pegol.","volume":"47","author":"Mizutani","year":"2020","journal-title":"J Dermatol"},{"key":"R36-20250503","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1136\/annrheumdis-2013-204231","article-title":"Efficacy of certolizumab pegol on signs and symptoms of axial spondyloarthritis including ankylosing spondylitis: 24-week results of a double-blind randomised placebo-controlled Phase 3 study.","volume":"73","author":"Landew\u00e9","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"R37-20250503","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1002\/art.38973","article-title":"Effect of certolizumab pegol over ninety-six weeks in patients with axial spondyloarthritis: results from a phase III randomized trial.","volume":"67","author":"Sieper","year":"2015","journal-title":"Arthritis Rheumatol"},{"key":"R38-20250503","doi-asserted-by":"crossref","first-page":"e000942","DOI":"10.1136\/rmdopen-2019-000942","article-title":"Long-term safety of certolizumab pegol in rheumatoid arthritis, axial spondyloarthritis, psoriatic arthritis, psoriasis and Crohn\u2019s disease: a pooled analysis of 11,317 patients across clinical trials.","volume":"5","author":"Curtis","year":"2019","journal-title":"RMD Open"},{"key":"R39-20250503","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1016\/j.it.2017.01.006","article-title":"IL-17 signaling: the Yin and the Yang.","volume":"38","author":"Amatya","year":"2017","journal-title":"Trends Immunol"},{"key":"R40-20250503","doi-asserted-by":"crossref","first-page":"108402","DOI":"10.1016\/j.intimp.2021.108402","article-title":"The role of IL-17 and anti-IL-17 agents in the immunopathogenesis and management of autoimmune and inflammatory diseases.","volume":"102","author":"Berry","year":"2022","journal-title":"Int Immunopharmacol"},{"key":"R41-20250503","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1038\/s41584-019-0294-7","article-title":"The IL-23-IL-17 pathway as a therapeutic target in axial spondyloarthritis.","volume":"15","author":"Sieper","year":"2019","journal-title":"Nat Rev Rheumatol"},{"key":"R42-20250503","doi-asserted-by":"crossref","first-page":"1661","DOI":"10.1002\/acr.23534","article-title":"Characterization of patients with ankylosing spondylitis and nonradiographic axial spondyloarthritis in the US-based Corrona registry.","volume":"70","author":"Mease","year":"2018","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"R43-20250503","first-page":"4343","article-title":"Association of secukinumab treatment with tuberculosis reactivation in patients with psoriasis, psoriatic arthritis, or ankylosing spondylitis [published correction appears in JAMA Dermatol. 2021 Jan 1;157(1):124].","volume":"157","author":"Elewski","year":"2021","journal-title":"JAMA Dermatol"},{"key":"R44-20250503","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1007\/s40265-019-01075-3","article-title":"Secukinumab: a review in ankylosing spondylitis [published correction appears in Drugs. 2019 Mar;79(4):445. doi: 10.1007\/s40265-019-01089-x].","volume":"79","author":"Blair","year":"2019","journal-title":"Drugs"},{"key":"R46-20250503","doi-asserted-by":"crossref","first-page":"2441","DOI":"10.1016\/S0140-6736(18)31946-9","article-title":"Ixekizumab, an interleukin-17A antagonist in the treatment of ankylosing spondylitis or radiographic axial spondyloarthritis in patients previously untreated with biological disease-modifying anti-rheumatic drugs (COAST-V): 16 week results of a phase 3 randomised, double-blind, active-controlled and placebo-controlled trial.","volume":"392","author":"van der Heijde","year":"2018","journal-title":"Lancet"},{"key":"R47-20250503","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1080\/1744666X.2020.1803063","article-title":"Ixekizumab for the treatment of ankylosing spondylitis.","volume":"16","author":"Huang","year":"2020","journal-title":"Expert Rev Clin Immunol"},{"key":"R48-20250503","doi-asserted-by":"crossref","first-page":"1894","DOI":"10.3389\/fimmu.2020.01894","article-title":"Bimekizumab, a novel humanized IgG1 antibody that neutralizes both IL-17A and IL-17F.","volume":"11","author":"Adams","year":"2020","journal-title":"Front Immunol"},{"key":"R49-20250503","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1136\/ard-2022-223595","article-title":"Efficacy and safety of bimekizumab in axial spondyloarthritis: results of two parallel phase 3 randomised controlled trials [published correction appears in Ann Rheum Dis. 2023 Sep;82(9):e213].","volume":"82","author":"van der Heijde","year":"2023","journal-title":"Ann Rheum Dis"},{"key":"R50-20250503","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1056\/NEJMoa2102388","article-title":"Bimekizumab versus adalimumab in plaque psoriasis.","volume":"385","author":"Warren","year":"2021","journal-title":"N Engl J Med"},{"key":"R51-20250503","doi-asserted-by":"crossref","first-page":"141","DOI":"10.2147\/ITT.S259126","article-title":"Anti-IL-17 Agents in the treatment of axial spondyloarthritis.","volume":"10","author":"Atzeni","year":"2021","journal-title":"Immunotargets Ther"},{"key":"R52-20250503","first-page":"1","article-title":"Brodalumab: a review of safety.","volume":"23","author":"Rusta-Sallehy","year":"2018","journal-title":"Skin Therapy Lett"},{"key":"R53-20250503","first-page":"27","article-title":"Primary efficacy of netakimab, a novel interleukin-17 inhibitor, in the treatment of active ankylosing spondylitis in adults.","volume":"38","author":"Erdes","year":"2020","journal-title":"Clin Exp Rheumatol"},{"key":"R54-20250503","first-page":"718","article-title":"Response to netakimab in radiographic axial spondyloarthritis patients with different baseline C-reactive protein, sacroiliitis evaluated by MRI and peripheral joint involvement status: a post-hoc analysis of the ASTERA study.","volume":"41","author":"Mazurov","year":"2023","journal-title":"Clin Exp Rheumatol"},{"key":"R55-20250503","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1038\/nature07537","article-title":"A human natural killer cell subset provides an innate source of IL-22 for mucosal immunity.","volume":"457","author":"Cella","year":"2009","journal-title":"Nature"},{"key":"R56-20250503","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/S1471-4906(03)00067-X","article-title":"Novel IL-12 family members shed light on the orchestration of Th1 responses.","volume":"24","author":"Brombacher","year":"2003","journal-title":"Trends Immunol"},{"key":"R57-20250503","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1097\/BOR.0000000000000301","article-title":"Targeting the interleukin-23\/17 axis in axial spondyloarthritis.","volume":"28","author":"Paine","year":"2016","journal-title":"Curr Opin Rheumatol"},{"key":"R58-20250503","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1056\/NEJMoa1900750","article-title":"Ustekinumab as induction and maintenance therapy for ulcerative colitis.","volume":"381","author":"Sands","year":"2019","journal-title":"N Engl J Med"},{"key":"R59-20250503","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1136\/annrheumdis-2013-204248","article-title":"Ustekinumab for the treatment of patients with active ankylosing spondylitis: results of a 28-week, prospective, open-label, proof-of-concept study (TOPAS).","volume":"73","author":"Poddubnyy","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"R60-20250503","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1007\/s40265-019-01136-7","article-title":"Risankizumab: first global approval.","volume":"79","author":"McKeage","year":"2019","journal-title":"Drugs"},{"key":"R61-20250503","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1136\/annrheumdis-2018-213328","article-title":"Risankizumab, an IL-23 inhibitor, for ankylosing spondylitis: results of a randomised, double-blind, placebo-controlled, proof-of-concept, dose-finding phase 2 study.","volume":"77","author":"Baeten","year":"2018","journal-title":"Ann Rheum Dis"},{"key":"R62-20250503","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1038\/s41584-022-00797-1","article-title":"IL-1 and autoinflammatory disease: biology, pathogenesis and therapeutic targeting.","volume":"18","author":"Broderick","year":"2022","journal-title":"Nat Rev Rheumatol"},{"key":"R63-20250503","doi-asserted-by":"crossref","first-page":"102785","DOI":"10.1016\/j.autrev.2021.102785","article-title":"The revisited role of interleukin-1 alpha and beta in autoimmune and inflammatory disorders and in comorbidities.","volume":"20","author":"Galozzi","year":"2021","journal-title":"Autoimmun Rev"},{"key":"R64-20250503","doi-asserted-by":"crossref","first-page":"102763","DOI":"10.1016\/j.autrev.2021.102763","article-title":"Interleukin 1\u03b1: a comprehensive review on the role of IL-1\u03b1 in the pathogenesis and treatment of autoimmune and inflammatory diseases.","volume":"20","author":"Cavalli","year":"2021","journal-title":"Autoimmun Rev"},{"key":"R65-20250503","first-page":"CD005121","article-title":"Anakinra for rheumatoid arthritis.","author":"Mertens","year":"2009","journal-title":"Cochrane Database Syst Rev"},{"key":"R66-20250503","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1136\/ard.2004.023176","article-title":"Open label trial of anakinra in active ankylosing spondylitis over 24 weeks.","volume":"64","author":"Haibel","year":"2005","journal-title":"Ann Rheum Dis"},{"key":"R67-20250503","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1136\/ard.2004.020800","article-title":"Efficacy of anakinra in active ankylosing spondylitis: a clinical and magnetic resonance imaging study.","volume":"63","author":"Tan","year":"2004","journal-title":"Ann Rheum Dis"},{"key":"R68-20250503","doi-asserted-by":"crossref","first-page":"a016295","DOI":"10.1101\/cshperspect.a016295","article-title":"IL-6 in inflammation, immunity, and disease.","volume":"6","author":"Tanaka","year":"2014","journal-title":"Cold Spring Harb Perspect Biol"},{"key":"R69-20250503","doi-asserted-by":"crossref","first-page":"1865","DOI":"10.1007\/s40265-017-0829-7","article-title":"Tocilizumab: a review in rheumatoid arthritis [published correction appears in Drugs. 2017 Dec 19;:].","volume":"77","author":"Scott","year":"2017","journal-title":"Drugs"},{"key":"R70-20250503","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1136\/annrheumdis-2013-203559","article-title":"Assessment of short-term symptomatic efficacy of tocilizumab in ankylosing spondylitis: results of randomised, placebo-controlled trials.","volume":"73","author":"Sieper","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"R71-20250503","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.3899\/jrheum.110955","article-title":"Interleukin 6 blockade in spondyloarthritis.","volume":"39","author":"Koumakis","year":"2012","journal-title":"J Rheumatol"},{"key":"R72-20250503","doi-asserted-by":"crossref","first-page":"1990","DOI":"10.3389\/fimmu.2019.01990","article-title":"Systematic review of safety and efficacy of rituximab in treating immune-mediated disorders.","volume":"10","author":"Kaegi","year":"2019","journal-title":"Front Immunol"},{"key":"R73-20250503","doi-asserted-by":"crossref","first-page":"143","DOI":"10.12659\/AJCR.900563","article-title":"Rituximab can induce remission in a patient with ankylosing spondylitis who failed anti-TNF-\u03b1 Agent.","volume":"18","author":"AlDhaheri","year":"2017","journal-title":"Am J Case Rep"},{"key":"R74-20250503","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1136\/annrheumdis-2012-201926","article-title":"One-year follow-up of ankylosing spondylitis patients responding to rituximab treatment and re-treated in case of a flare.","volume":"72","author":"Song","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"R75-20250503","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1111\/1756-185X.13510","article-title":"2018 APLAR axial spondyloarthritis treatment recommendations.","volume":"22","author":"Tam","year":"2019","journal-title":"Int J Rheum Dis"},{"key":"R76-20250503","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1097\/BOR.0000000000001020","article-title":"Axial spondyloarthritis guidelines: aiming for maximum impact.","volume":"36","author":"Choufani","year":"2024","journal-title":"Curr Opin Rheumatol"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000040742","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,4]],"date-time":"2025-05-04T00:03:01Z","timestamp":1746316981000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000040742"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,29]]},"references-count":74,"journal-issue":{"issue":"48","published-print":{"date-parts":[[2024]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000040742","relation":{},"ISSN":["1536-5964"],"issn-type":[{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,11,29]]}}}